Ultraviolet A Combined with Narrow-Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow-Band Ultraviolet B: A Retrospective Cohort Study

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2023-09-01 DOI:10.1155/2023/8865065

I. Amitay-Laish, H. Prag Naveh, R. Holzman, Ali Abo Baker, Adi Raviv, R. Friedland, D. Ben Amitai, O. Reiter, Michael David, E. Hodak

{"title":"Ultraviolet A Combined with Narrow-Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow-Band Ultraviolet B: A Retrospective Cohort Study","authors":"I. Amitay-Laish, H. Prag Naveh, R. Holzman, Ali Abo Baker, Adi Raviv, R. Friedland, D. Ben Amitai, O. Reiter, Michael David, E. Hodak","doi":"10.1155/2023/8865065","DOIUrl":null,"url":null,"abstract":"Background. Psoralen plus ultraviolet A (PUVA) is the preferred phototherapeutic modality for early-stage folliculotropic mycosis fungoides (FMF), and for early-stage non-FMF refractory to narrow-band ultraviolet B (NBUVB). However, PUVA has a problematic safety profile. Literature on the treatment with the combination of UVA and NBUVB for MF is sparse. Objective. To evaluate the effectiveness of UVA combined with NBUVB for early-stage MF, specifically for FMF and NBUVB-refractory non-FMF, in adult and pediatric patients. Methods. A retrospective analysis was conducted for patients treated with UVA combined with NBUVB at our center, during 1/2008–8/2022. Results. The cohort included 51 patients: 35 adults and 16 pediatric patients. The overall response rate (ORR) of 39 patients with early-FMF (25 adults and 14 children) was 95%, and the complete response (CR) was 62%. No significant differences in ORR/CR rates were noted between adult and pediatric patients. Of 12 patients with non-FMF (10 adults and 2 children), the ORR was 83% and the CR was 50%. In 17 patients (8 FMF and 9 non-FMF), prior NBUVB therapy resulted in partial response/stable disease; yet, UVA + NBUVB led to CR in 9 patients (4 FMF and 5 non-FMF). Side effects were minimal. Conclusion. Combined UVA and NBUVB is a good alternative to PUVA for adult or pediatric patients with early-stage MF , with FMF or non-FMF refractory to NBUVB.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/8865065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background. Psoralen plus ultraviolet A (PUVA) is the preferred phototherapeutic modality for early-stage folliculotropic mycosis fungoides (FMF), and for early-stage non-FMF refractory to narrow-band ultraviolet B (NBUVB). However, PUVA has a problematic safety profile. Literature on the treatment with the combination of UVA and NBUVB for MF is sparse. Objective. To evaluate the effectiveness of UVA combined with NBUVB for early-stage MF, specifically for FMF and NBUVB-refractory non-FMF, in adult and pediatric patients. Methods. A retrospective analysis was conducted for patients treated with UVA combined with NBUVB at our center, during 1/2008–8/2022. Results. The cohort included 51 patients: 35 adults and 16 pediatric patients. The overall response rate (ORR) of 39 patients with early-FMF (25 adults and 14 children) was 95%, and the complete response (CR) was 62%. No significant differences in ORR/CR rates were noted between adult and pediatric patients. Of 12 patients with non-FMF (10 adults and 2 children), the ORR was 83% and the CR was 50%. In 17 patients (8 FMF and 9 non-FMF), prior NBUVB therapy resulted in partial response/stable disease; yet, UVA + NBUVB led to CR in 9 patients (4 FMF and 5 non-FMF). Side effects were minimal. Conclusion. Combined UVA and NBUVB is a good alternative to PUVA for adult or pediatric patients with early-stage MF , with FMF or non-FMF refractory to NBUVB.

查看原文本刊更多论文

紫外线A联合窄波段紫外线B是治疗早期毛囊萎缩性蕈样肉芽肿和窄波段紫外线难治性蕈状肉芽肿的有效方法：回顾性队列研究

背景。补骨脂素加紫外线A (PUVA)是早期嗜滤泡性蕈样真菌病(FMF)和对窄带紫外线B (NBUVB)难治的早期非FMF的首选光疗方式。然而，PUVA的安全性存在问题。关于UVA和NBUVB联合治疗MF的文献很少。目标。评估UVA联合NBUVB治疗早期MF的有效性，特别是治疗成人和儿童患者的FMF和NBUVB难治性非FMF。方法。回顾性分析2008年1月至2022年8月期间在我中心接受UVA联合NBUVB治疗的患者。结果。该队列包括51名患者:35名成人和16名儿科患者。39例早期fmf患者(成人25例，儿童14例)总缓解率(ORR)为95%，完全缓解率(CR)为62%。成人和儿童患者的ORR/CR率无显著差异。在12例非fmf患者(10例成人和2例儿童)中，ORR为83%，CR为50%。在17例患者(8例FMF和9例非FMF)中，先前的NBUVB治疗导致部分缓解/疾病稳定;然而，UVA + NBUVB导致9例CR(4例FMF和5例非FMF)。副作用很小。结论。联合UVA和NBUVB是成人或儿童早期MF患者(FMF或非FMF对NBUVB难治)的良好替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.